While pharmaceutical companies and medical device firms know that working together is a vital part of doing business, they “live in 2 different world in many ways,” Minnetronix co-founder Dirk Smith said last week at the annual Drug Delivery Partnerships conference. From development timelines to regulatory approval pathways, it can sometimes seem like pharma and medtech companies are […]
Sanofi-Aventis
Nordisk tumbles on lowered outlook
Shares in Novo Nordisk (NYSE:NVO) fell -9% this morning after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results and lowered its outlook for 2017. The Danish company posted profits of 8.7 billion Danish kroner, or $1.26 billion USD, on sales of 29.57 billion kroner for the 3 months ended Dec. 31, for bottom-line growth of […]
Insulin makers face class-action lawsuit over price collusion
A class-action lawsuit filed in the U.S. District Court of Massachusetts alleges that insulin makers Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other based on real market prices. In the last 5 years, the 3 companies […]
Johnson & Johnson to pay $30B for Actelion
After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]
Sanofi’s Suliqua combination therapy approved in European Union
Sanofi (NYSE:SNY) said today that the European Commission granted marketing authorization in Europe for its Suliqua combination product for adults with type II diabetes. The therapy is a fixed-ratio combination of basal insulin glargine and lixisenatide, intended to be used with metformin to improve patients’ glycemic control. Suliqua will be available in 2 pre-filled SoloSTAR pens at […]
Sanofi sues Nordisk over Tresiba marketing claims in U.S.
Sanofi (NYSE:SNY) said yesterday that it is suing competitor Novo Nordisk (NYSE:NVO) for “misleading” marketing materials that claim Sanofi’s insulin drugs Lantus and Toujeo will be “blocked” by U.S. pharmacy benefit manager CVS Caremark in January and that patients should switch to Nordisk’s Tresiba. CVS is replacing both Sanofi’s and Nordisk’s drugs with Eli Lilly’s Basaglar on […]
Actelion, J&J re-enter takeover negotations
Actelion (VTX:ATLN) and Johnson & Johnson (NYSE:JNJ) have re-entered talks to reach a takeover deal, after the US healthcare giant reportedly abandoned its efforts last week. Some suggest that this could mean the end of Sanofi‘s (NYSE:SNY) attempt to make a deal with the Swiss biotech firm, according to Reuters. J&J and Actelion had been engaged in informal talks […]
Actelion gains on Sanofi deal rumors
Actelion (VTX:ATLN) shares jumped more than 8% to 214 Swiss francs after reports that Sanofi (NYSE:SNY) and the Swiss biotech are nearing a takeover deal that would value Actelion at $29.6 billion. After Johnson & Johnson (NYSE:JNJ) abandoned its efforts to reach an agreement with Actelion this week, Sanofi stepped in to pursue negotiations. Sanofi is expected to offer […]
Lilly, Boehringer’s Basaglar long-acting insulin now available in the U.S.
Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that its insulin glargine injection, Basaglar, is available by prescription in the U.S. Basaglar is a long-acting insulin with the same amino acid sequence as Sanofi‘s (NYSE:SNY) Lantus. The companies also offer resources for patients beginning insulin treatment, including an app for smartphones and tablets which provides […]
Actelion, Sanofi in talks after J&J backs out of negotiations
Actelion (VTX:ATLN) and Sanofi (NYSE:SNY) are reportedly in talks to reach a takeover deal after Johnson & Johnson (NYSE:JNJ) said yesterday that it has closed negotiations with the Swiss biotech. J&J and Actelion have been in informal talks for nearly 2 months and the US company has made an offer valued at 250 Swiss francs per share. J&J said yesterday […]
Sanofi throws hat in the ring with J&J’s in Actelion pursuit
Sanofi (NYSE:SNY) is reportedly considering a bid for Actelion Pharmaceuticals (VTX:ATLN), competing with an offer made to the Swiss biotech by Johnson & Johnson (NYSE:JNJ). Bloomberg reported that Sanofi is working with advisers to assess its options and has made its interest known informally to Actelion. The French drugmaker has not made a formal comment on the matter […]